Akero Therapeutics ((AKRO)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Akero Therapeutics is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.’ The study aims to assess the safety and efficacy of Efruxifermin (EFX) in treating patients with NASH/MASH and fibrosis, a significant health concern due to its potential to progress to cirrhosis and liver failure.
The intervention being tested is Efruxifermin, administered via subcutaneous injection. It is designed to improve liver health in patients with NASH/MASH by reducing liver fat and fibrosis.
This interventional study is randomized with a parallel assignment model, involving a quadruple masking approach to ensure unbiased results. The primary purpose is treatment, focusing on the therapeutic effects of Efruxifermin.
The study began on December 1, 2023, with primary completion expected by August 2025. The last update was submitted on August 18, 2025, indicating ongoing progress.
The outcome of this study could significantly influence Akero Therapeutics’ stock performance, given the high unmet need for effective NASH treatments. Success could position Akero as a leader in this space, potentially impacting investor sentiment positively. Competitors in the NASH treatment market will be closely monitoring these developments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.